A Phase II, Randomized, Placebo Controlled Study to Evaluate the Efficacy of the Combination of Gefitinib and Metformin in Patients With Locally Advanced and Metastatic Non-Small-Cell-Lung-Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Jan 2018
At a glance
- Drugs Gefitinib (Primary) ; Metformin (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms CGMT
- 10 Jun 2017 Biomarkers information updated
- 01 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 11 May 2015 Planned primary completion date changed from 1 May 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov record.